Anti-s100a monoclonal antibody and preparation method and application thereof

By tandemly generating the S100A protein using genetic engineering methods and expressing it in HEK293 cells, a stable and highly specific anti-S100A monoclonal antibody was prepared, solving the problems of high cost and poor stability in traditional methods and achieving standardized production.

CN115819577BActive Publication Date: 2026-06-12HENAN CELNOVTE BIOTECHNOLOGY CO LTD
2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
HENAN CELNOVTE BIOTECHNOLOGY CO LTD
Filing Date
2022-10-08
Publication Date
2026-06-12

AI Technical Summary

⚠Technical Problem

Existing S100A monoclonal antibodies are expensive to produce, lack specificity and stability, exhibit large batch-to-batch variations, and pose risks in traditional production processes.

⚗Method used

Anti-S100A monoclonal antibodies were prepared using genetic engineering methods. By tandem two full-length S100A proteins and adding a linker, immunogenicity was increased. The antibodies were expressed and purified using HEK293 cells, avoiding the risks of traditional methods.

🎯Benefits of technology

This approach achieves stable antibody properties, good specificity and affinity, and good reproducibility, avoiding the risks associated with traditional methods and providing a standardized production process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The application discloses an anti-S100A monoclonal antibody and a preparation method and application thereof. The anti-S100A monoclonal antibody provided by the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO:1-3, and VLCDR1 with the amino acid sequence shown in SEQ ID NO:4, VLCDR3 shown in SEQ ID NO:6 and VLCDR2 with the amino acid sequence DTS. The nucleotide sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody are also provided, and the recombinant antibody can be prepared by using a genetic engineering technology. The method is a standardized antibody production process, avoids risk factors in a traditional monoclonal antibody production and preservation process, and has the advantages of stable property, high experimental repeatability and the like. The recombinant antibody can specifically react with the S100A protein and has high sensitivity.
Need to check novelty before this filing date? Find Prior Art